NTV Asset Management LLC Sells 700 Shares of Abbott Laboratories (ABT)

NTV Asset Management LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,164 shares of the healthcare product maker’s stock after selling 700 shares during the period. NTV Asset Management LLC’s holdings in Abbott Laboratories were worth $3,050,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ABT. Heritage Way Advisors LLC boosted its holdings in Abbott Laboratories by 2.6% during the fourth quarter. Heritage Way Advisors LLC now owns 45,293 shares of the healthcare product maker’s stock worth $3,276,000 after purchasing an additional 1,128 shares during the last quarter. Heritage Investors Management Corp lifted its stake in Abbott Laboratories by 3.7% in the fourth quarter. Heritage Investors Management Corp now owns 53,159 shares of the healthcare product maker’s stock valued at $3,845,000 after acquiring an additional 1,876 shares during the last quarter. Norris Perne & French LLP MI lifted its stake in Abbott Laboratories by 0.8% in the fourth quarter. Norris Perne & French LLP MI now owns 283,252 shares of the healthcare product maker’s stock valued at $20,488,000 after acquiring an additional 2,341 shares during the last quarter. First National Trust Co lifted its stake in Abbott Laboratories by 12.9% in the fourth quarter. First National Trust Co now owns 124,728 shares of the healthcare product maker’s stock valued at $9,022,000 after acquiring an additional 14,243 shares during the last quarter. Finally, Rothschild Investment Corp IL lifted its stake in Abbott Laboratories by 10.5% in the fourth quarter. Rothschild Investment Corp IL now owns 86,785 shares of the healthcare product maker’s stock valued at $6,277,000 after acquiring an additional 8,263 shares during the last quarter. 74.36% of the stock is owned by institutional investors and hedge funds.

ABT has been the subject of a number of recent analyst reports. Morgan Stanley increased their price target on shares of Abbott Laboratories from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday, January 2nd. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a research note on Monday, January 28th. Goldman Sachs Group upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their price target for the company from $78.00 to $81.00 in a research note on Friday, November 30th. Citigroup cut shares of Abbott Laboratories from a “neutral” rating to a “sell” rating and cut their price target for the company from $72.00 to $68.00 in a research note on Wednesday, January 2nd. Finally, Credit Suisse Group initiated coverage on shares of Abbott Laboratories in a research note on Monday, December 17th. They issued an “outperform” rating and a $82.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have assigned a buy rating to the stock. Abbott Laboratories has an average rating of “Buy” and a consensus price target of $79.48.

In other news, Chairman Miles D. White sold 142,341 shares of the stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $72.35, for a total value of $10,298,371.35. Following the transaction, the chairman now directly owns 3,459,185 shares of the company’s stock, valued at $250,272,034.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John G. Stratton acquired 3,455 shares of the company’s stock in a transaction dated Thursday, January 31st. The stock was bought at an average cost of $72.32 per share, for a total transaction of $249,865.60. Following the completion of the transaction, the director now directly owns 3,558 shares of the company’s stock, valued at $257,314.56. The disclosure for this purchase can be found here. 0.74% of the stock is owned by corporate insiders.

Shares of ABT opened at $75.06 on Wednesday. The stock has a market capitalization of $128.79 billion, a PE ratio of 26.06, a P/E/G ratio of 1.95 and a beta of 1.14. Abbott Laboratories has a fifty-two week low of $56.81 and a fifty-two week high of $75.23. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.13 and a current ratio of 1.42.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.81. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.50%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.74 earnings per share. Equities research analysts anticipate that Abbott Laboratories will post 3.2 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be given a $0.32 dividend. The ex-dividend date is Monday, January 14th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.28. This represents a $1.28 annualized dividend and a dividend yield of 1.71%. Abbott Laboratories’s dividend payout ratio is presently 44.44%.

WARNING: “NTV Asset Management LLC Sells 700 Shares of Abbott Laboratories (ABT)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2019/02/13/ntv-asset-management-llc-sells-700-shares-of-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Featured Story: What is a stock split?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit